Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
Recap: Cidara Therapeutics Q2 Earnings
Cidara Therapeutics (NASDAQ:CDTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Cidara Therapeutics Q2 EPS $(0.19) Down From $0.18 YoY
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.19) per share. This is a 205.56 percent decrease over earnings of $0.18 per share from the same period last year.
Short Volatility Alert: Cidara Therapeutics, Inc.
On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72.
The overall sentiment for CDTX has been Bearish.
Short Volatility Alert: Cidara Therapeutics, Inc.
On Friday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.785.
The overall sentiment for CDTX has been Bearish.
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
Cidara Pursues FDA Approval For Bloodstream Infections Candidate
Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and invasive candidiasis.
